Patent intelligence · WO
WO 2025137347
FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION
FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION
Patent details — WO 2025137347
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jun 26, 2025
- Expiration
- Jun 21, 2045
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 39/ 395 A I, A61K/3939591
Quick answer
WO 2025137347 (FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION) is held by ABBVIE INC [US]. Status: granted. Granted Jun 26, 2025. Expires Jun 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K/3939591
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2025137347?
WO 2025137347 (FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION) is held by ABBVIE INC [US]. Status: granted. Granted Jun 26, 2025. Expires Jun 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025137347?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does WO 2025137347 expire?
Our index shows an expiration date of Jun 21, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.